2026-2034年全球羥氯喹市場規模、佔有率、趨勢和成長分析報告

預計羥氯喹市場將從 2025 年的 20.3 億美元成長到 2034 年的 59.9 億美元，2026 年至 2034 年的複合年成長率為 12.78%。

由於羥氯喹廣泛用於治療某些自體免疫疾病和感染疾病，其全球市場規模不斷擴大。羥氯喹是治療類風濕性關節炎和紅斑性狼瘡等疾病的常用處方藥。該藥物透過調節免疫系統活性和減輕發炎作用發揮作用，幫助控制慢性自體免疫疾病患者的症狀。

羥氯喹的主要市場促進因素包括自體免疫疾病盛行率的上升以及人們對現有治療方案的認知不斷提高。醫療專業人員依賴羥氯喹作為長期疾病管理的成熟治療方法。製藥公司持續生產和分銷該藥物，以滿足全球醫療保健系統的穩定需求。

展望未來，由於羥氯喹在自體免疫疾病治療中的持續應用，預計其市場將保持穩定成長。對更有效的治療策略和疾病管理技術的研究將支撐其持續需求。此外，發展中地區醫療保健覆蓋範圍的擴大也有助於提高該藥物的供應量。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球羥氯喹市場：依內容分類

• 市場分析、洞察與預測
• 200 mg
• 400 mg
• 800 mg

第5章 全球羥氯喹市場：依等級分類

• 市場分析、洞察與預測
• USP標準級
• EP標準級
• 醫藥級
• 其他

第6章：全球羥氯喹市場：依藥物類別分類

• 市場分析、洞察與預測
• 抗瘧疾藥
• 用於治療風濕病的羥氯喹製劑
• 狼瘡抑制劑羥氯喹製劑
• 羥氯喹製劑
• 羥氯喹製劑用於感染疾病新冠肺炎

第7章 全球羥氯喹市場：依劑型分類

• 市場分析、洞察與預測
• 藥片
• 其他

第8章：全球羥氯喹市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 其他

第9章 全球羥氯喹市場：依最終用戶分類

• 市場分析、洞察與預測
• 醫院
• 專科診所
• 居家照護
• 其他

第10章 全球羥氯喹市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房
• 其他

第11章 全球羥氯喹市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第12章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第13章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Actiza Pharmaceutical Private Limited
  • AdvaCare Pharma
  • Ipca Laboratories Ltd
  • Bliss GVS Pharma Ltd
  • GeoVax
  • Sumaya Biotech
  • VLP Therapeutics
  • Osivax
  • Ajanta Pharma
  • Strides Pharma Science Limited
  • Mylan NV
  • Zydus Cadila
  • Cipla Inc
  • Sun Pharmaceutical Industries Ltd

The Hydroxychloroquine Market size is expected to reach USD 5.99 Billion in 2034 from USD 2.03 Billion (2025) growing at a CAGR of 12.78% during 2026-2034.

The global hydroxychloroquine market has grown due to its widespread use in treating certain autoimmune and infectious diseases. Hydroxychloroquine is a medication commonly prescribed for conditions such as rheumatoid arthritis and lupus. It works by modulating immune system activity and reducing inflammation, helping manage symptoms in patients with chronic autoimmune disorders.

Key drivers of the hydroxychloroquine market include increasing prevalence of autoimmune diseases and growing awareness about available treatment options. Healthcare providers rely on hydroxychloroquine as an established therapy for long-term disease management. Pharmaceutical companies continue to manufacture and distribute the medication to meet consistent demand in global healthcare systems.

Looking ahead, the hydroxychloroquine market is expected to maintain stable growth due to ongoing medical use in autoimmune disease treatment. Research into improved therapeutic strategies and better disease management practices will support continued demand. Expanding healthcare access in developing regions may also contribute to broader availability of the medication.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Strength

• 200 mg
• 400 mg
• 800 mg

By Grade

• USP Standards Grade
• EP Standards Grade
• Pharmaceutical Standards Grade
• Others

By Drug Class

• Antimalarial
• Anti-rheumatic Hydroxychloroquine Drug
• Lupus Suppressant Hydroxychloroquine Drug
• Hydroxychloroquine Drug
• Anti-COVID 19 Hydroxychloroquine Drug

By Dosage Forms

• Tablets
• Others

By Route of Administration

• Oral
• Others

By End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

COMPANIES PROFILED

• Actiza Pharmaceutical Private Limited, AdvaCare Pharma, Ipca Laboratories Ltd, Bliss GVS Pharma Ltd, GeoVax, Sumaya Biotech, VLP Therapeutics, Osivax, Ajanta Pharma, Strides Pharma Science Limited, Mylan NV, Zydus Cadila, Cipla Inc, Sun Pharmaceutical Industries Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL HYDROXYCHLOROQUINE MARKET: BY STRENGTH 2022-2034 (USD MN and Kilo Tons)

• 4.1. Market Analysis, Insights and Forecast Strength
• 4.2. 200 mg Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
• 4.3. 400 mg Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
• 4.4. 800 mg Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)

Chapter 5. GLOBAL HYDROXYCHLOROQUINE MARKET: BY GRADE 2022-2034 (USD MN and Kilo Tons)

• 5.1. Market Analysis, Insights and Forecast Grade
• 5.2. USP Standards Grade Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
• 5.3. EP Standards Grade Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
• 5.4. Pharmaceutical Standards Grade Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)

Chapter 6. GLOBAL HYDROXYCHLOROQUINE MARKET: BY DRUG CLASS 2022-2034 (USD MN and Kilo Tons)

• 6.1. Market Analysis, Insights and Forecast Drug Class
• 6.2. Antimalarial Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
• 6.3. Anti-rheumatic Hydroxychloroquine Drug Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
• 6.4. Lupus Suppressant Hydroxychloroquine Drug Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
• 6.5. Hydroxychloroquine Drug Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
• 6.6. Anti-COVID 19 Hydroxychloroquine Drug Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)

Chapter 7. GLOBAL HYDROXYCHLOROQUINE MARKET: BY DOSAGE FORMS 2022-2034 (USD MN and Kilo Tons)

• 7.1. Market Analysis, Insights and Forecast Dosage Forms
• 7.2. Tablets Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
• 7.3. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)

Chapter 8. GLOBAL HYDROXYCHLOROQUINE MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN and Kilo Tons)

• 8.1. Market Analysis, Insights and Forecast Route Of Administration
• 8.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
• 8.3. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)

Chapter 9. GLOBAL HYDROXYCHLOROQUINE MARKET: BY END-USERS 2022-2034 (USD MN and Kilo Tons)

• 9.1. Market Analysis, Insights and Forecast End-users
• 9.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
• 9.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
• 9.4. Homecare Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
• 9.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)

Chapter 10. GLOBAL HYDROXYCHLOROQUINE MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN and Kilo Tons)

• 10.1. Market Analysis, Insights and Forecast Distribution Channel
• 10.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
• 10.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
• 10.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
• 10.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)

Chapter 11. GLOBAL HYDROXYCHLOROQUINE MARKET: BY REGION 2022-2034(USD MN and Kilo Tons)

• 11.1. Regional Outlook
• 11.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Kilo Tons)
  • 11.2.1 By Strength
  • 11.2.2 By Grade
  • 11.2.3 By Drug Class
  • 11.2.4 By Dosage Forms
  • 11.2.5 By Route Of Administration
  • 11.2.6 By End-users
  • 11.2.7 By Distribution Channel
  • 11.2.8 United States
  • 11.2.9 Canada
  • 11.2.10 Mexico
• 11.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Kilo Tons)
  • 11.3.1 By Strength
  • 11.3.2 By Grade
  • 11.3.3 By Drug Class
  • 11.3.4 By Dosage Forms
  • 11.3.5 By Route Of Administration
  • 11.3.6 By End-users
  • 11.3.7 By Distribution Channel
  • 11.3.8 United Kingdom
  • 11.3.9 France
  • 11.3.10 Germany
  • 11.3.11 Italy
  • 11.3.12 Russia
  • 11.3.13 Rest Of Europe
• 11.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Kilo Tons)
  • 11.4.1 By Strength
  • 11.4.2 By Grade
  • 11.4.3 By Drug Class
  • 11.4.4 By Dosage Forms
  • 11.4.5 By Route Of Administration
  • 11.4.6 By End-users
  • 11.4.7 By Distribution Channel
  • 11.4.8 India
  • 11.4.9 Japan
  • 11.4.10 South Korea
  • 11.4.11 Australia
  • 11.4.12 South East Asia
  • 11.4.13 Rest Of Asia Pacific
• 11.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Kilo Tons)
  • 11.5.1 By Strength
  • 11.5.2 By Grade
  • 11.5.3 By Drug Class
  • 11.5.4 By Dosage Forms
  • 11.5.5 By Route Of Administration
  • 11.5.6 By End-users
  • 11.5.7 By Distribution Channel
  • 11.5.8 Brazil
  • 11.5.9 Argentina
  • 11.5.10 Peru
  • 11.5.11 Chile
  • 11.5.12 South East Asia
  • 11.5.13 Rest of Latin America
• 11.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Kilo Tons)
  • 11.6.1 By Strength
  • 11.6.2 By Grade
  • 11.6.3 By Drug Class
  • 11.6.4 By Dosage Forms
  • 11.6.5 By Route Of Administration
  • 11.6.6 By End-users
  • 11.6.7 By Distribution Channel
  • 11.6.8 Saudi Arabia
  • 11.6.9 UAE
  • 11.6.10 Israel
  • 11.6.11 South Africa
  • 11.6.12 Rest of the Middle East And Africa

Chapter 12. COMPETITIVE LANDSCAPE

• 12.1. Recent Developments
• 12.2. Company Categorization
• 12.3. Supply Chain & Channel Partners (based on availability)
• 12.4. Market Share & Positioning Analysis (based on availability)
• 12.5. Vendor Landscape (based on availability)
• 12.6. Strategy Mapping

Chapter 13. COMPANY PROFILES OF GLOBAL HYDROXYCHLOROQUINE INDUSTRY

• 13.1. Top Companies Market Share Analysis
• 13.2. Company Profiles
  • 13.2.1 Actiza Pharmaceutical Private Limited
  • 13.2.2 AdvaCare Pharma
  • 13.2.3 Ipca Laboratories Ltd
  • 13.2.4 Bliss GVS Pharma Ltd
  • 13.2.5 GeoVax
  • 13.2.6 Sumaya Biotech
  • 13.2.7 VLP Therapeutics
  • 13.2.8 Osivax
  • 13.2.9 Ajanta Pharma
  • 13.2.10 Strides Pharma Science Limited
  • 13.2.11 Mylan N.V
  • 13.2.12 Zydus Cadila
  • 13.2.13 Cipla Inc
  • 13.2.14 Sun Pharmaceutical Industries Ltd